ANDA 207757, held by Zydus Pharms. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 207757 (Doxycycline), held by Zydus Pharms, was first approved by FDA on Sep 28, 2017, with 2 approved supplements and 0 published complete response letters.
INDICATIONS To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline for injection and other antibacterial drugs, doxycycline for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 28, 2017 | Original application | Approved | None posted |
| DoxycyclineEQ 100MG BASE/VIAL · injectable;injection | Doxycycline Hyclate | Rx |
| DoxycyclineEQ 200MG BASE/VIAL · injectable;injection | Doxycycline Hyclate | Rx |
| Mar 31, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 8, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 28, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters